In a nutshell This study investigated the occurrence and impact of bone loss in adult patients with lymphoma and leukemia. This study concluded that these patients have significant bone loss compared to the general population. Some background Bone loss is a known consequence of many cancers and their treatments. In healthy adults, bone loss is...
Read MoreType of leukemia-Chronic lymphocytic leukemia (CLL) Posts on Medivizor
The effect of other conditions on ibrutinib treatment of CLL
In a nutshell The study looked at the impact of other medical conditions (comorbidities) on the effectiveness of ibrutinib (Imbruvica) in the treatment of chronic lymphocytic leukemia (CLL). The study concluded that having a number of other conditions was associated with a poorer prognosis in CLL patients treated with ibrutinib. Some background...
Read MoreCombining obinutuzumab and bendamustine for chronic lymphocytic leukemia patients
In a nutshell This study aimed to investigate the effectiveness of an obinutuzumab and bendamustine combination in chronic lymphocytic leukemia patients. This study concluded that this combination appears to be effective in these patients and has manageable side effects. Some background Obinutuzumab (Gazyva) is a monoclonal antibody. Monoclonal...
Read MoreVenetoclax for chronic lymphocytic leukemia patients with 17p deletion
In a nutshell This study aimed to investigate the effectiveness of venetoclax in chronic lymphocytic leukemia patients with 17p deletion. This study concluded that venetoclax is effective in this group of patients. Some background 17p deletion chronic lymphocytic leukemia (17p del CLL) is a type of CLL that has a poor prognosis.Venetoclax...
Read MoreLenalidomide and blood clots: low risk in CLL and NHL
In a nutshell This study examined the risk of venous thromboembolism (VTE, a blood clot that forms in the veins of the legs, arms, or groin) in patients treated with lenalidomide (Revlimid). The study concluded that the risk of VTE was low with lenalidomide treatment. Some background Lenalidomide is an effective treatment already used in multiple...
Read MoreImpact of severe side effects on outcomes of older patients with CLL
In a nutshell This study examined whether newer therapies for chronic lymphocytic leukemia (CLL) were associated with higher odds of negative side effects in older patients. The study concluded that CLL patients over age 65 experienced more serious side effects than younger patients. Some background Chronic lymphocytic leukemia (CLL) is commonly...
Read MoreA new treatment combination for patients with relapsed/refractory chronic lymphocytic leukemia
In a nutshell This study aimed to investigate the effectiveness of venetoclax (Venclexta) and rituximab (Rituxan) treatment in patients with relapsed/refractory chronic lymphocytic leukemia. This study concluded that venetoclax-rituximab treatment was effective for these patients. Some background Chronic lymphocytic leukemia...
Read MoreWhat are the long-term outcomes following bendamustine treatment?
In a nutshell This study examined the long-term safety and effectiveness of bendamustine (Treanda) in lymphoma and leukemia. This study concluded that bendamustine is a safe and effective therapy for these patients. Some background Bendamustine has been shown to have high effectiveness and few side effects for a wide range of lymphomas. This drug is...
Read MoreFirst-line treatment with ibrutinib – a review
In a nutshell This study outlined recent evidence on the use of ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL). Some background Tyrosine kinase inhibitor therapy is a type of immunotherapy that blocks signals needed for tumors to grow. This includes the Bruton tyrosine kinase inhibitor ibrutinib. Ibrutinib blocks a signal that keeps the...
Read MoreRituximab, cladribine and cyclophosphamide: Early results of a new treatment combination with and without maintenance therapy
In a nutshell This study examined a new treatment combination known as RCC followed by rituximab (Rituxan) maintenance therapy for chronic lymphocytic leukemia (CLL). These results support the safety and effectiveness of RCC followed by rituximab maintenance therapy. Risk factors of disease progression were identified. Some background The chemotherapy...
Read MorePromising early results with venetoclax in patients previously treated with idelalisib
In a nutshell This study examined venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) previously treated with idelalisib (Zydelig). Researchers reported good response rates and a low rate of side effects for venetoclax after idelalisib. Some background Targeted therapy is the standard treatment of CLL. This includes the...
Read MoreGood response rates to venetoclax in patients previously treated with ibrutinib
In a nutshell This study examined venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) previously treated with ibrutinib (Imbruvica). Researchers reported good disease control and a low rate of side effects venetoclax after ibrutinib. Some background Targeted therapy is the standard treatment of CLL. This includes the Bruton...
Read More
